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Abstract
Background: Estrogen signaling plays a critical role in a number of normal physiological processes
and has important implications in the treatment of breast cancer. The p160 nuclear receptor
coactivator, AIB1 (amplified in breast cancer 1), is frequently amplified and overexpressed in human
breast cancer and has been shown to enhance estrogen-dependent transactivation.
Methods:  To better understand the molecular and physiological consequences of AIB1
overexpression in breast cancer cells, an AIB1 cDNA was transfected into the low AIB1 expressing,
estrogen-receptor (ER) negative breast cancer cell line, MDA-MB-436. The features of a derivative
cell line, designated 436.1, which expresses high levels of AIB1, are described and compared with
the parental cell line.
Results: A significant increase in the levels of CREB binding protein (CBP) was observed in 436.1
cells and immunofluorescent staining revealed altered AIB1 and CBP staining patterns compared to
the parental cells. Further, transient transfection assays demonstrated that the overall estrogen-
dependent transactivation in 436.1 cells is approximately 20-fold higher than the parental cells and
the estrogen dose-response curve is repositioned to the right. Finally, cDNA microarray analysis
of approximately 7,100 cDNAs identified a number of differentially expressed genes in the 436.1
cells.
Conclusion:  These observations lend insight into downstream signaling pathways that are
influenced by AIB1.
Background
Estrogen hormone action is an essential regulator of phys-
iologic responses ranging from reproductive development
and function to bone formation and fat metabolism.
Estrogens have also been considered one of the major
adverse factors in the pathogenesis of breast cancer, the
second leading cause of cancer-related deaths in American
women [1,2].
Estrogen action is mediated through the estrogen recep-
tors, ER-α and ER-β, members of the nuclear hormone
receptor superfamily [3,4]. Also critical to estrogen signal-
ing are the interactions of ER-α with transcriptional coac-
tivators including p/CAF, CREB binding protein (CBP),
p300, and the p160 family members (reviewed in [5]). It
isthought that the coactivators activate transcription
through the modification of histonesand the bridging of
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sequence specific transcription factors, including nuclear
receptors, to the pre-initiation complex. Moreover, tran-
scriptional activation through ER-α depends upon an
ordered assembly of coactivator proteins on and off the
promoter of the targetgene in a cyclic fashion [6,7]. This
selective modulation of cofactor assembly potentially
contributes to the tightly regulated pattern of tissue-spe-
cific estrogen response.
The p160 coactivator, AIB1, was identified during a search
for genes that are frequently amplified in human breast
cancer [8]. The frequent gene amplification and overex-
pression of AIB1 in ER-positive human breast cancers is
hypothesized to confer a selective growth advantage
through increased hormone signaling [8,9]. While it is
likely that overexpression of AIB1 contributes to tumori-
genesis through this mechanism, overexpression of AIB1
has also been observed in breast tumors that are ER-nega-
tive, suggesting increased expression of AIB1  perturbs
additional signaling pathways which may have important
implications in the absence of ER [10].
In the present study, low AIB1  expressing, ER-negative
breast cancer cells, MDA-MB-436, were transfected with
the human AIB1 cDNA and selected for stable expression
of AIB1. One of the clones expresses high levels of AIB1
message and protein and is referred to as 436.1. These
cells were used to investigate estrogen receptor activity in
transient transfection assays and cDNA microarray analy-
sis was performed to identify differentially expressed
genes. Here, we report the characterization of the 436.1
cell line and suggest that it may be a useful tool for exam-
ining the effects of AIB1 overexpression on a variety of sig-
naling pathways.
Methods
The breast cancer cell line, MDA-MB-436, was obtained
from the American Type Culture Collection (ATCC) and
cultured in RPMI 1640 medium (Life Technologies) con-
taining 10% fetal bovine serum. Stable transfections were
performed using the standard calcium-phosphate tech-
nique using the CalPhos Maximizer System (Clontech)
according to the manufacturer's recommended proce-
dures. To generate stablytransfected lines, MDA-MB-436
cells were seeded at 1.5 × 105 cells per well into 6-well cul-
ture dishes (20 mm2) and grown overnight. Cells were
transfected with 2.0 µg pcDNA3.1-AIB1 (described in [8])
or empty pcDNA3.1 vector (Invitrogen) and refed thefol-
lowing day. After 48 hours, cells were transferred to 100
mm2  dishes and selected in culture medium supple-
mented with 500 µg/ml neomycin (G418) (Life Technol-
ogies). After approximately three weeks, neomycin-
resistant colonies were isolated usingcloning rings and
transferred to 12-well dishes for expansion.
RNA was extracted from exponentially growing cells using
the RNeasy kit (Qiagen). Following extraction, 10–15 µg
of total RNA was electrophoresed in a 1.0 % formamide/
formaldehyde agarose gel and transferred by standard
methods [11]. An RNA ladder, 0.24–9.5 kb (Life Technol-
ogies), was used as a molecular size marker. Hybridiza-
tion was performed using a 32P-dCTP random-primed 2.2
kb Not/SacI fragment of pCMVSPORT-B11 as probe
(described in [8]).
For Western blot analyses, cells were harvested and lysed
in RIPA buffer (1X PBS, 1% NP40, 0.5% sodium deoxy-
cholate, 0.1% SDS) containing complete protease inhibi-
tor cocktail (Boehringer Mannheim). Cellular lysates were
collected after centrifugation at 10,000 × g for 15 minutes.
Approximately 100 µg of total protein was denatured by
boiling for three minutes in sample loading buffer
(Novex) and separated by SDS-polyacrylamide gel electro-
phoresis. To examine proteins from transient transfection
assays, a total of 3 × 10 µl of cell extract from each tripli-
cate was pooled for Western analysis. Resolved proteins
were transferred onto nylon membranes and blockedo-
vernight at 4°C in 5% milk/PBS. AIB1 protein was
detected by chemiluminescenceusing a mouse mono-
clonal antibody, AX15.2 [12]. Estrogen receptor and CBP
were detected using the anti-ER-α polyclonal antibody
HC-20 and the anti-CBP antibody A-11 (Santa Cruz Bio-
technology), respectively. Secondary antibodies used were
HRP-goatanti-mouse IgG Fc specific and HRP goat anti-
rabbit IgG (Jackson Immunoresearch) and detection was
done using the ECL chemiluminescent substrate (Amer-
sham) and exposing to autoradiography film (Hyperfilm-
ECL, Amersham).
For fluorescent microscopy, adherent cells were grown on
Falcon culture slides (Becton Dickenson) to 70% conflu-
ency. Cells were fixed with 2% paraformaldehyde, perme-
abolized with 1:1 methanol/acetone and blocked with 5%
normal goat serum/1% casein/0.5% BSA/0.2% Triton X-
100. Cells were incubated with 1:5 dilution of anti-AIB1
mAb AAP.1 hybridoma culture supernatant [13] and anti-
CBP for 1 hour at room temperature. After washing with
PBS, the cells were incubated with 2 µg/ml Rhodamine-
conjugated goat anti-mouse IgG and 2 µg/ml FITC-conju-
gated goat anti-rabbit IgG (Jackson Immunoresearch) for
1 hour at room temperature. Following a finalwash, DAPI
mounting media and coverslips were added and slides
were analyzed using a fluorescent microscope (Zeiss
Axiophot).
To examine the effects of estrogen, cells were transiently
transfected using Lipofectamine transfection reagent (Life
Technologies). The transfections were performed with 1.0
µg pGL3. luc.3ERE or pTK. luc. ERE reporter vectors, 0.4 or
10 ng of pHEGO-hyg (wild type estrogen receptor codingBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/22
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sequence plus hygromycin resistance, ATCC), and 5.0 ng
ofpRL-tk (Renilla null luciferase reporter; Promega). The
day following transfection, cells were incubated in the
absence or presence of varying concentrations of 17β-
estradiol or 100 nM 4-hydroxytamoxifen. Cell lysates
were harvested 48 hours post transfection and reporter
activities were determined using the Dual Luciferase
Reporter Assay system (Promega) and the supplier's rec-
ommended methods. The pGL3. luc.3ERE, which con-
tains three tandem copies of the ERE upstream the Simian
Virus 40 promoter driving the luciferase gene, was the
kind gift of Fern Merdoch (University of Wisconsin). The
tk. ERE. luc, which contains three ERE upstream the thy-
midine kinase promoter, was giftfrom Susan Fuqua (Bay-
lor University). The activity for subsaturating
concentrations of 17β-estradiol was expressed as percent
of maximal activity with saturating concentrations of 17β-
estradiol (10 nM). In cases in which saturation was
reached at concentrations below 10 nM 17β-estradiol, an
average of the maximal activities was utilized to deter-
mine percent of maximal activity. The results are
expressed in relative luciferaseactivity (Luciferase/
Renilla.).
cDNA microarray preparation and analyses were per-
formed according to standard NHGRI protocol http://
www.nhgri.nih.gov/DIR/Microarray/main.html. Microar-
rays consisted of 7,088 known human genes. Briefly, RNA
was extracted from cells using TRIzol purification (Life
Technologies) followed by purification with the RNeasy
kit (Qiagen). Sixty to 80 µg total RNA was fluorescently
labeled with Cy5-dUTP or Cy3-dUTP (Amersham) using
oligo-(dT)-primed reverse transcriptase (Superscript II,
Life Technologies) and hybridized to PCR products
immobilized on glass slides. Fluorescent images were
acquired using a custom-designed confocal scanner
equipped for dual laser excitation at the appropriate wave-
lengths. Pseudo-colored images were obtained by placing
one fluorescent image into the green channel and the
other into the red channel. A detection method was then
employed to determine the actual target region based on
the information from both red and green pixel values
[14]. The ratios of the red intensity to the green intensity
(R/G) for all targets were determined and normalized
with 88 preselected internal control genes. The hybridiza-
tion quality of each target area was based on fluorescence
intensity background and signal to noise ratio, as
described in detail at http://www.nhgri.nih.gov/DIR/
Microarray/main.html.
Results
MDA-MB-436 cells were transfected with an expression
vector containing the full-length human AIB1 cDNA and
cultured in the presence of neomycin for the selection of
stable transfectants. While numerous resistant colonies
were selected for expansion, the majority gradually died
following culture passage. The viable colonies were
expanded and characterized. Additionally, five independ-
ently transfected populations were selected en masse and
expanded for characterization.
To determine if the transfected cells expressed the exoge-
nous AIB1 cDNA, RNAs from viable clonal populations
were analyzed by Northern blot. One of the clones, desig-
nated 436.1, showed significant expression of the pre-
dicted 5.7 kb transcript (Fig. 1A). This transcript was not
detected in other transfected clones (e.g., 436.5) or in five
en masse selected populations (data not shown), suggest-
ing the exogenous AIB1 cDNA was not highly expressed in
these cell populations. Next, Western blot analysis of
whole cell lysates from the parental MDA-MB-436 and the
436.1 cells was performed to ascertain if 436.1 cells dis-
played increased AIB1 protein. Figure 1B shows high lev-
els of AIB1 protein in the 436.1 cells compared to the
parental cells. Taken together, these results illustrate that
the 436.1 cells integrated and significantly expressed the
transfected AIB1 cDNA.
Previous reports have demonstrated compensatory effects
of p160 coactivator expression levels with the loss of one
of the p160 coactivators [15,16]. In SRC-1 knockout mice,
for example, the expression of TIF2 is increased in certain
tissues. To examine if the increase in AIB1 mRNA expres-
sion in 436.1 cells was paralleled by changes in SRC-1 or
TIF2  coactivator levels, the Northern blot was stripped
and hybridized with cDNAs of SRC-1 and TIF2. Densito-
metric measurements indicated approximately 10% and
15% reduction in the expression levels of SRC-1 and TIF2,
respectively, in the 436.1 cells compared to the MDA-MB-
436 parental cells or the AIB1 transfected cell line, 436.5,
which failed to express the 5.7 kb transcript (Fig. 1C).
To determine if the levels of the general co-integrator pro-
teins, CBP or p300, had changed in the 436.1 cells, the
Western blot from Figure 1B was stripped and probed
with either anti-CBP or anti-p300 antibodies. Interest-
ingly, a significant increase in the levels of CBP protein
was observed in the 436.1 cells compared to the parental
cells, whereas levels of p300 appeared slightly reduced
(Fig. 1D).
The 436.1 cells are morphologically distinct from the
parental MDA-MB-436 cells. While the MDA-MB-436
cells display a typical epithelial morphology, the most
conspicuous feature of the 436.1 population was the
appearance of giant cells with abundant cytoplasm, often
exhibiting multiple nuclei or a multilobular nucleus (Fig.
2).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/22
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The cellular distribution of AIB1 protein in MDA-MB-436
and 436.1 cells was examined by immunofluorescence
(Fig. 3). AIB1 staining of MDA-MB-436 cells produced a
diffuse nuclear and faint cytoplasmic pattern (Fig. 3A). In
addition to the nuclear staining, bright speckles were
localized to the nucleoli in some cells. AIB1 distribution
in the majority of 436.1 cells was similar to that observed
in the parental MDA-MB-436 line, but the staining
appeared brighter and more granular (Fig. 3B). The
brighter speckles localized in the nucleoli were also appar-
ent and often arranged at the nucleolar periphery.
The majority (~99%) of 436.1 cells showed bright diffuse
nuclear and cytoplasmic AIB1 staining, yet additional
staining patterns of AIB1 were also seen in 436.1 cells that
were not apparent in the parental MDA-MB-436 cells.
Some of the cells displayed bright, dot-like nuclear AIB1
staining (Fig. 3C) or had reduced nuclear signal with
profound cytoplasmic staining (Fig. 3D) that appeared to
be concentrated in cytoplasmic organelles.
Since Western blot analysis revealed increased levels of
CBP protein in the 436.1 cells, an anti-CBP antibody was
used for immunofluorescent detection of endogenous
CBP in each of the cell lines. Interestingly, CBP staining
was faint and homogeneously diffuse throughout the
nucleus in the MDA-MB-436 cells (Fig. 3A); while in the
436.1 cells, three or more bright, dot-like foci appeared in
the nucleus, in addition to the diffuse nuclear staining
(Fig. 3B,3C,3D). These results suggest upregulation of
CBP leads to altered protein distribution within the cells.
A clear correlation between the number of CBP dots and
the different AIB1 staining patterns could not be
Analysis of coactivator RNA and protein levels in BT474 and  wild-type and AIB1-transfected MDA-MB-436 cells Figure 1
Analysis of coactivator RNA and protein levels in BT474 and 
wild-type and AIB1-transfected MDA-MB-436 cells. (A) RNAs 
from AIB1 transfected 436.1 and 436.5 cells, and breast can-
cer cell lines, BT474 and MDA-MB-436, were analyzed by 
Northern blot. All cell lines expressed a full-length endog-
enous AIB1 transcript of 9.0 kb, whereas a transcript of 5.7 
kb derived from the exogenous AIB1 cDNA was detected in 
an AIB1 transfectant (436.1). The corresponding ethidium 
bromide-stained gel indicates equivalent loading. (B) Whole 
cell lysates from wild-type MDA-MB-436 and from AIB1-
transfected 436.1 cells were analyzed by Western blot. The 
160 kDa AIB1 protein was detected in both cell lines, with 
increased amounts seen in AIB1-transfected 436.1 cells. 
Tubulin is included as a loading control. (C) The membrane 
used in A was stripped and hybridized with probes for SRC-1 
or TIF2 cDNAs. (D) The membrane used in B was stripped 
and probed with anti-CBP and anti-p300 antibodies.
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Comparison of the cellular characteristics of MDA-MB-436  and the transfected, 436.1 cell morphology was examined  using a Nikon microscope equipped with 10× and 20×  objectives Figure 2
Comparison of the cellular characteristics of MDA-MB-436 
and the transfected, 436.1 cells. MDA-MB-436 and 436.1 cell 
morphology was examined using a Nikon microscope 
equipped with 10× and 20× objectives. Images were captured 
using a 35 mm Nikon camera. Note the large, cells with mul-
tilobular nuclei in the 436.1 culture (bracket).
MDA-MB-436 436.1
100X
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Page 5 of 11
(page number not for citation purposes)
established, though in a few cells some CBP dots co-local-
ized with AIB1 dots (data not shown).
The results described above demonstrate that the 436.1
cells have integrated andexpressed exogenous AIB1, with
small reductions in the expression of TIF2 and SRC-1, and
a large increase in CBP levels. The effects of these altera-
tions on estrogen receptor-α dependent transactivation in
436.1 cells were examined in transient transfection assays
using an ER reporter and varying concentrations of an
estrogen receptor-α expression plasmid. An estrogen-
induced response was seen in both cell lines, but the
436.1 cellsdisplayed a dramatic increase (approximately
20-fold) in the overall luciferase reporter gene activity
compared with the parental line (Fig. 4). The increase in
luciferase activity in 436.1 cells was observed in both the
absence and presence of added ligand. Moreover, an
increase in reporter activity was also observed with
increasing amounts of transfected receptor (50 ng to 500
ng). These results suggest increased expression of AIB1
and CBP augments the capacity of 436.1 cells to assemble
functional ER/ERE coregulator complexes.
The dose-response curve for a particular steroid predicts
the biological response of the exposed cell to a given con-
centration of ligand. Since the levels of transactivation
were profoundly higher in 436.1 cells compared to MDA-
MB-436 cells, we asked if the estrogen dose-response
curve was modified in the 436.1 line compared to MDA-
MB-436 cells. For these studies, different concentrations
of ER were used to ascertain that the receptor was limiting
and that increased response is obtained over a range of
steroidconcentrations. Thus, transient transfections were
performed in which 0.4 ng and 10 ng of ER-α plasmid
were transfected into MDA-MB-436 and 436.1 cells and
incubated with increasing concentrations of 17β-estra-
diol. In 436.1 cells, increasing amounts of ER-α from 0.4
ng to 10 ng increased reporter gene expression at each
concentration of steroid (Fig. 5A). To determine if the
dose-response curve of estradiol has been altered by the
addition of ER-α, the data from Figure 5A is replotted as a
percent of the maximal activity induced by a saturating
concentration of 17β-estradiol (Fig. 5B). Significantly,
concentrations. The the dose-response curve is shifted to a
Immunofluorescence of AIB1 and CBP in MDA-MB-436 (top  row) and 436.1 (bracket) cells Figure 3
Immunofluorescence of AIB1 and CBP in MDA-MB-436 (top 
row) and 436.1 (bracket) cells. Primary antibodies are as indi-
cated. The cells were fixed at approximately 70% confluency 
and counterstained with DAPI (first panel). Red corresponds 
to AIB1 staining revealed with the Cy3-conjugated secondary 
goat anti-mouse antibody (second panel) and green corre-
sponds to CBP staining with fluorescein isothiocyanate-con-
jugated goat anti-rabbit secondary antibody (third panel). The 
DAPI, AIB1, and CBP images from the same field of cells are 
merged in the last panel.
DAPI Anti-AIB1 Anti-CBP Merged
A
B
C
D
MDA-MB-436
436.1
AIB1 transfected 436.1 cells display increased reporter gene  activity Figure 4
AIB1 transfected 436.1 cells display increased reporter gene 
activity. Cells weretransiently transfected with increasing 
amounts of estrogen receptor expression plasmidand 1.5 ug 
of pGL3. ERE. luc reporter vector and incubated in the pres-
ence or absence of ethanol (EtOH), 10 nM 17β-estradiol 
(E2), or 100 nM 4-hydroxytamoxifen (Tam). Results are rep-
resentative of three experiments. Relative luciferase activity 
= Luciferase/Renilla.
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lower EC50 with higher ER-α average left shift in the dose-
response curve was 2.2 ± 0.33 fold (SEM, n = 8, P =
0.0085) with increasing ER-α plasmid. This effect was also
seen in the MDA-MB-436 cells, but total gene expression
reached maximal activity at a much lower ligand concen-
tration. Figure 5C illustrates the dose-response curves of
both MDA-MB-436 and 436.1 cellstransfected with 0.4 ng
ER-α. The EC50 of 13 ± 4 pM (SEM, n = 5) in MDA-MB-
436cells was significantly right shifted in 436.1 cells to
118 ± 20 pM (SEM, n = 8, P = 0.0016 by Mann-Whitney
test) 17β-estradiol.
Next, we determined if the increased levels of AIB1 and
CBP coactivators in 436.1 cells modified the levels of
transfected ER-α. Cellular lysates from MDA-MB-436 and
436.1 cells transfected with 10 ng and 100 ng of ER-α were
analyzed by Western blot. The levels of full length ER-α
protein were not significantly increased in the 436.1 cells
relative to the parental cells, indicating the observed
increase in ER-dependenttransactivation in these cells is
not the result of increased receptor levels (Fig. 5D).
Finally, cDNA microarray analysis was performed to
examine endogenous gene expression [8] in the 436.1
cells compared to MDA-MB-436, and to identify potential
downstream effects of AIB1 overexpression. Total RNAs
from MDA-MB-436 and 436.1 cells were reverse-tran-
scribed and labeled with fluorescent Cy3 and Cy5 dyes.
Replicate experiments were also performed in which the
fluorescent labels were reversed. Labeled RNAs were
hybridized to a cDNA microarray containing 7,088
cDNAs arrayed on a glass slide. Out of 3,658 genes which
met hybridization quality criteria (see methods), a total of
94 and 87 genes were upregulated and downregulated,
respectively, by a factor of 3 or more in 436.1 cells com-
pared to MDA-MB-436 cells. The 30 most significant out-
liers in each category are listed in Table 1 [see additional
file 1].
Discussion
Vast epidemiological data supports a causative role for
estrogens in the development of human breast cancer.
Though significant progress has been made in the identi-
fication and characterization of a large number of proteins
that participate in estrogen signaling, the precise molecu-
lar mechanisms that control specific cellular responses to
endogenous and exogenous ligands of the ER signaling
pathway are complex and not completely understood.
However, increased understanding of hormone action
suggests that the cell type and/or co-regulator levels dic-
tate the ultimate response to ligand. The present study was
initiated to examine the cellular and molecular conse-
quences of AIB1 overexpression.
Our previous report demonstrated that the majority of ER-
positive breast cancer cell lines have correspondingly high
levels of endogenous AIB1 expression (four out of five cell
lines analyzed); therefore, the number of suitable cell
lines in which to generate stable overexpression of AIB1
are limiting [8]. Of interest, transfection of the AIB1 cDNA
into the ER-positive, low AIB1-expressing cell line, T47-D,
demonstrated a cell-lethal phenotype and no subclones
with high levels of AIB1 expression were generated (data
not shown).
Likewise, transfection of AIB1 into MDA-MB-436 breast
cancer cells appears to be lethal since all but one of the
surviving subclones failed to demonstrate expression of
the transfected AIB1. The 436.1 line discussed in this
study, however, has integrated the exogenous AIB1 cDNA
and maintained high levels of AIB1 mRNA and protein
expression. Most likely, 436.1 cells have acquired addi-
tional alterations which support its survival.
Though the parental MDA-MB-436 cells are ER-α nega-
tive, transient transfection of ERα was capable of inducing
expression of an ERE-regulated reporter gene in the pres-
ence of estrogen, indicating these cells contain sufficient
amounts of co-regulatory factors required for estrogen
inducibility. Furthermore, since the levels of ER-α could
be experimentally modulated in transient tranfection
studies, this derivative cell line provided a useful model to
compare the effects of low-level, constitutive versus high-
level expression of AIB1 in the presence or absence of var-
ying concentrations of ER-α.
Immunostaining patterns of AIB1 and CBP included dif-
fuse fluorescent staining as well as large, bright, dot-like
foci (Fig. 3). Although the punctate-staining pattern of
AIB1 in 436.1 cells resembled CBP containing PML (pro-
myelocytic leukemia protein) oncogenic domain (POD)-
like structures [17,18], the AIB1 dots appeared in only a
small percentage of the population (< 2%) and typically
did not overlap with CBP. Analyses of populations
derived from single cell isolates revealed that the punctate
staining was not a clonal variant. Similarly, Baumann et al
used GFP-fused to GRIP1 to investigate its intracellular
distribution in HeLa cells and observed both diffuse and
focal accumulation of GRIP1 [19]. CBP staining, on the
other hand, was consistently diffuse throughout the
nucleus in MDA-MB-436 cells but appeared to accumulate
in PML-like bodies in the AIB1-transfected 436.1 cells.
These results are consistent with observations made
recently by Boisvert et al [20]; several cell lines do not
accumulate CBP into PML bodies, but transfection of a
GFP-CBP fusion protein into these cells leads to accumu-
lation of CBP into distinct PML nuclear bodies. Taken
together, these observations imply that increased
amounts of AIB1 and CBP have caused the redistributionBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/22
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Dose-dependent stimulation of luciferase activity by 17β-estradiol Figure 5
Dose-dependent stimulation of luciferase activity by 17β-estradiol. MDA-MB-436 and 436.1 cells were transiently transfected 
with 0.4 or 10 ng of estrogen receptor plasmid (pHEGO-hyg) and incubated in the presence of ethanol or increasing amounts 
of 17β-estradiol. The total levels of luciferase seen with ethanol and varying levels 17β-estradiol in 436.1 cells are plotted in 
(A). The data from (A) was replotted in (B) as a percentage of the maximal activity with 10 nM 17β-estradiol, as described in 
the Materials and Methods section. To facilitate direct comparison of the position of the dose-response curves for the two cell 
lines, the data from (A) and that obtained with MDA-MB-436 cells with 0.4 ng ER (data not shown) is illustrated in panel (C). 
The data are representative of eight (436.1) and five (MDA-MB-436) experiments. (D) Whole cell lysates from ER-positive 
BT474 and MCF-7 breast cancer cells and transiently transfected MDA-MB-436 and 436.1 cells were analyzed by Western blot. 
The 58 kDa ER protein (arrow) was detected in ER-positive BT474 and MCF-7 cells, as well as both cell lines that were trans-
fected with 10 and 100 ng of ER.
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of these proteins into nuclear foci in 436.1 cells. Perhaps
the levels of CBP and AIB1 are below the level required for
recruitment to nuclear bodies in the non-transfected
MDA-MB-436 cells. The mechanisms for upregulation of
CBP in 436.1 cells remain elusive, but it will be interesting
to determine if overexpression of AIB1 plays a direct role
in the transcriptional regulation of CBP, or if levels of CBP
are sensitized to and somehow adjusted with levels of
AIB1, or vise versa.
While the overall level of reporter gene activity was dra-
matically increased in 436.1 cells, perhaps the most strik-
ing observation is in the right in the shift of the estrogen
dose-response curve in 436.1 cells. The repositioning of
the E2 dose-response curve to the right in 436.1 cells was
somewhat unexpected since several studies with other
receptors have demonstrated a left shift in the dose-
response curve with the addition of p160 proteins, includ-
ing TIF2 and SRC-1 [21–24]. However, there is no evi-
dence that the total levels of transactivation and the
position of the dose-response curve are linked. Studies
with glucocorticoid [21,25–28] and progesterone [22,28]
receptors show that the two phenomena can be totally
disconnected. Increased total transactivation might be
expected if the concentrations of two coactivators (AIB1
and CBP) are increased, but this does not predict the
effects of these changes on the dose-response curve and
EC50.
One explanation for these observations is squelching,
where increased levels of AIB1 compete for some limiting
factor that is crucial for nuclear receptor transactivation,
such as CBP. Because we have also demonstrated that the
levels of CBP are significantly elevated in the 436.1 cells it
is unlikely that the level of CBP is limiting. However, AIB1
and CBP could be competing for a common factor that is
now limiting due to AIB1 and CBP abundance [24]. Also,
cell specific differences, which have caused some
coactivators and corepressors to be apparently inactive
[21,22] or to have opposite activities [22,28], may be
important.
We propose a hypothetical model to explain the increase
in total transactivation and the overall right-shift in the
dose-response curve, as schematized in Figure 6. In this
model, the dose-response curve depends on the presence
of a ternary complex composed of AIB1, CBP, and a third,
unknown nuclear receptor complex participant, depicted
as X. In MDA-MB-436 cells, the levels of AIB1, CBP, and
factor X, are at concentrations sufficient to form ternary
AIB1/CBP/X complexes that support the observed dose-
response curve. The absence or dramatic reduction of such
a ternary AIB1/CBP/X complex in 436.1 cells (due to
increased levels of AIB1 and CBP and limiting levels of X)
might result in a very different EC50. In fact, by the law of
mass action, elevated levels of AIB1 and CBP would be
expected to cause increased levels of the dimeric com-
plexes (i.e., AIB1/X, AIB1/CBP, and CBP/X). Each of these
may cause increased transactivation but not permit the
same positioning of the dose-response curve as in MDA-
MB-436 cells, resulting in a relative increase in the EC50
and a right shift in the dose-response curve. The greatly
decreased levels in 436.1 cells of the ternary AIB1/CBP/X
complex, which has no effect on the level of total transac-
tivation, would now have only minimal effects of the
positioning of the dose-response curve.
Additional support for this model comes from several
lines of evidence. First, convincing evidence for a limiting
factor other than p160 coactivators has been demon-
strated by Lopez et al. [23]. These investigators have
shown that squelching between different receptors cannot
be relieved by supplying excess amounts of CBP or p160
coactivator and suggest there is an unknown factor that is
necessary for receptor coactivation. Similarly, Kino et al
reported that the amount of CBP that is required to see a
decrease in glucocorticoid receptor (GR) transactivation is
cell dependent [29]. The presence of a limiting complex
component that participates in the positioning of the
dose-response curve has been established by Chen et al
[24]. Here, the effects of modulators (GR, TIF2, or a cis-
acting element in the reporter gene) were additive when
all components were limiting, but no further effect was
obtained if saturating amounts of any one modulator was
present. Second, there is a well established physical inter-
action between CBP/p300 and p160 coactivators [13,30–
32], and several groups have proposed that CBP and other
coregulators, e.g., p160s, exist in the cytoplasm in pre-
formed complexes [33,34].
Candidate genes whose altered expression might contrib-
ute to the phenotypic features of the 436.1 cells, such as
cell survival, multinucleated morphology, and transcrip-
tional properties were identified by cDNA microarray
technology. Comparison of RNAs from MDA-MB-436 ver-
sus 436.1 revealed a number of profound changes in the
expression of genes with a variety of functions, including
cell adhesion, communication, maintenance of cell
shape, apoptosis, and cell cycle control. For example, cyc-
lin D3, an important regulator of endomitosis and poly-
ploidization in megakaryocytes [35], was upregulated
3.75-fold in 436.1 cells, suggesting upregulation of cyclin
D3 contributed to the altered morphological features
observed in these cells. An 8.2-fold upregulation of the
apoptosisinhibitor 2 gene may have facilitated the sur-
vival of these cells. Downregulation of NFkB and C/EBPβ
cDNAs (ratios of 0.3 and 0.5, respectively) and a number
of interleukins whose gene expression are regulated by
these transcription factors (Table 1) possibly indicates a
shift away from NFkB and C/EBPβ signaling toBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/22
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transcriptional activities mediated by other transcription
factors. Finally, none of the general transcription factors,
including TFIIA (ratio = 1.1), TFIIB (ratio = 1.0), TFIID
(ratio=.53), TFIIE (ratio = 1.25), TFIIF polypeptides 1 and
2 (ratio = 0.63, 0.94), and TFIIH (ratio = 1.16) showed
increased expression in 436.1 cells, supporting the idea
that AIB1 and CBP overexpression play a significant role
in the observed increase in basal and E2-induced reporter
gene activity in 436.1 cells. Future studies are necessary to
confirm these observations and to determine which are
genes regulated by transcriptional complexes containing
AIB1.
In summary, we have characterized an AIB1-transfected
cell line that displays high levels of AIB1 expression. The
data presented here support a role for AIB1 in the estro-
gen-dose response and also suggest that, apart from ER-
mediated pathways, AIB1 contributes to a number of sig-
naling events which influence cell cycle, morphology, and
survival. Future efforts directed at determining how
overexpression of AIB1 affects cell behavior in the pres-
ence or absence of specific hormone receptors should
shed light onto specific signaling pathways that are altered
as a consequence of AIB1 amplification in breast cancer.
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A proposed model of how increased concentrations of AIB1 and CBP in 436.1 cells compete for a factor that is necessary for 
estrogen-induced transcription. As schematized on the left, transcriptional activation through the estrogen receptor relies on 
interaction with AIB1, CBP, and an unknown factor X. In MDA-MB-436 cells, none of these components are limiting. The 436.1 
cells have limited amounts of factor X and excess quantities of AIB1 and CBP, which compete for binding to factor X. The 
absence or presence of a ternary complex of AIB1/CBP/X in 436.1 cells affects the EC50 and transactivation, as schematized.
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